Home › Legal › Cannabis Medical Program Qualifying Conditions in Australia
⚐ Flag an error How this page was made
Also known as: Australian medicinal cannabis pathways · TGA cannabis access · Special Access Scheme cannabis

Cannabis Medical Program Qualifying Conditions in Australia

Australia's medicinal cannabis access system and how prescribing doctors evaluate eligibility.

Sourced and fact-checked
5 cited sources
Published
Last reviewed
How this page was made

This article is general information, not legal advice. Laws change; check current rules with official sources or a lawyer.

↯ The honest take

Australia doesn't have a formal list of qualifying conditions like some US states do. Instead, doctors can prescribe cannabis for any condition they think warrants it through two TGA pathways: the Special Access Scheme (case-by-case) or Authorised Prescribers (designated specialists). No condition is automatically 'approved'—it's up to the prescriber. Access remains expensive and rare despite the nominally permissive rules.

Australia does not operate a traditional medical cannabis 'program' with a pre-determined list of qualifying conditions. Cannabis products are regulated under the Therapeutic Goods Act 1989 (Cth) as prescription-only medicines Strong evidence[1]. The Therapeutic Goods Administration (TGA) oversees access through two primary pathways: the Special Access Scheme (SAS) and the Authorised Prescribers scheme Strong evidence[1].

There is no exhaustive list of 'approved' conditions. Instead, a prescribing doctor may seek access to a cannabis product for any patient, provided the doctor justifies the therapeutic use and the patient meets broad eligibility criteria. In practice, prescribers have typically focused on areas with published evidence: chronic pain, multiple sclerosis spasticity, chemotherapy-induced nausea, and treatment-resistant epilepsy.

Scheduling and product classification vary. Not all cannabis products are subject to the same regulatory pathway; cannabinoid content, dose, and form determine how a product is regulated and which access scheme applies. Many medicinal cannabis products accessed through TGA pathways are unapproved therapeutic goods obtained on a case-by-case basis rather than pre-registered products.

This is not legal advice. For guidance specific to your condition, eligibility, and legal status in your state or territory, consult a prescribing doctor and your state health regulator. TGA policy and state laws are subject to change.

Special Access Scheme (SAS)

The Special Access Scheme is the primary pathway for accessing unapproved cannabis products on a case-by-case basis Strong evidence[1]. The scheme is divided into two categories:

Category A (notification-based): Used for serious or life-threatening conditions. The prescriber notifies the TGA of the intended supply; no prior TGA approval is required Strong evidence[1].

Category B (individual application): Used for other conditions. The doctor submits an application to the TGA, providing clinical justification, patient history, and proposed product details Strong evidence[1]. The TGA assesses the application before allowing supply.

Key points:

Common conditions for which SAS has been used include chronic pain, treatment-resistant epilepsy, multiple sclerosis spasticity, and chemotherapy-induced nausea Weak / limited[2]. However, SAS data are not comprehensively published; exact approval rates by condition and detailed demographics are not publicly disclosed.

Authorised Prescribers Scheme

The Authorised Prescribers scheme allows practitioners with designated qualifications and experience to prescribe specified cannabis products directly, without requiring case-by-case TGA approval for each patient Strong evidence[1].

How it works:

Uptake and barriers: The scheme aims to streamline access for conditions where clinical evidence is more robust. However, uptake has remained limited. Practitioners must invest time in obtaining specialist status, and some regions have fewer authorised practitioners than others. Patients wishing to use this pathway should search the TGA's Authorised Prescribers Register to locate practitioners with relevant expertise in their condition or location Strong evidence[1].

Common Clinical Areas

Although Australia has no official qualifying-conditions list, cannabis has been prescribed most commonly for the following:

Chronic Pain Weak / limited[2] Neuropathic pain, cancer pain, and non-cancer chronic pain represent a significant proportion of SAS and Authorised Prescriber use in Australia Weak / limited[2].

Multiple Sclerosis Spasticity Weak / limited[2] Nabiximols (Sativex®), a 1:1 THC:CBD oromucosal spray, is registered in Australia for MS-related spasticity and is the most widely recognised approved cannabis product Strong evidence[1]. Whole-plant cannabis extracts are also prescribed off-label for this indication.

Chemotherapy-Induced Nausea and Vomiting (CINV) Weak / limited[2] Some international and Australian guidelines discuss cannabis for CINV, though product access in Australia for this indication is typically case-by-case rather than routine Weak / limited[2].

Treatment-Resistant Epilepsy Weak / limited[2] Particularly in children and adults who have failed conventional anticonvulsants. Cannabidiol (CBD) products are explored through SAS, though mainstream anticonvulsants remain first-line treatment.

Palliative Care Weak / limited[2] Apetite stimulation, pain, and anxiety in terminal illness or advanced disease; access is often coordinated through specialist palliative-care doctors.

Post-Traumatic Stress Disorder (PTSD) Anecdote Anecdotal reports exist; formal clinical evidence in Australian populations is limited, and access remains off-label.

No condition is automatically 'approved,' and prescriber discretion is paramount. Evidence levels vary widely, and most applications represent off-label use of imported or compounded cannabis products.

Access Barriers and Current Uptake

Despite a nominally permissive regulatory framework, medical cannabis access in Australia remains limited in practice.

Key barriers:

  1. Cost: Cannabis products are not subsidised by the PBS. Out-of-pocket costs vary substantially by product type, supplier, and dosage. Patients should obtain specific pricing from their prescriber or supplier No data.
  1. Prescriber uptake: Many GPs lack training in cannabis pharmacology and are hesitant to apply for SAS approval or seek Authorised Prescriber status. Specialist uptake, though higher in neurology and oncology, remains limited Weak / limited[2].
  1. Product availability: Licensed suppliers are relatively limited; imports may be delayed. Compounding pharmacies can prepare customised formulations but are subject to defined regulatory requirements Strong evidence[1].
  1. Clinical evidence gaps: For most conditions, Australian-specific trials are minimal. Prescribers often rely on international studies, small trials, or expert consensus Weak / limited[2].
  1. State-level variation: While medicinal cannabis is regulated at the Commonwealth level by the TGA, some states or territories may have additional local requirements or guidance that affect access Strong evidence[1]. Patients should verify current local requirements with their prescriber or state health authority.

These factors mean that even patients who would qualify under SAS or Authorised Prescribers criteria often cannot access products in practice due to cost, prescriber reluctance, or supply constraints.

Product Forms and Supply Requirements

Cannabis products must be sourced through legal channels: licensed suppliers or compounding pharmacies. Home-grown cannabis is prohibited for medical use Strong evidence[1].

Approved and common product forms include:

Cannabidiol (CBD): Standalone CBD products may be available through different regulatory pathways depending on dosage and formulation. Low-dose CBD products may be scheduled differently from high-strength CBD, which remains restricted Weak / limited[2].

Supply and compounding: Licensed compounding pharmacies can prepare customised cannabis products under TGA-defined requirements. Supply arrangements vary by product and supplier; patients should work with their prescriber to confirm product availability and legal supply routes.

How to Access: Practical Steps

Via Special Access Scheme (SAS):

  1. Consult a prescribing doctor (GP or specialist) experienced in cannabis or willing to assist Strong evidence[1].
  2. The doctor reviews your medical history, current condition, and whether conventional treatments have been inadequate or unsuitable Strong evidence[1].
  3. The doctor lodges an SAS application with the TGA, including clinical justification and your informed consent. Determine whether your condition qualifies for Category A (notification) or Category B (individual application) Strong evidence[1].
  4. The TGA assesses the application (Category B timelines vary by application); approval or rejection is notified to your doctor Strong evidence[1].
  5. If approved, your doctor provides a prescription to a licensed supplier or compounding pharmacy Strong evidence[1].
  6. You receive the product and pay full cost. Keep documentation of your prescription and product sourcing Strong evidence[1].

Via Authorised Prescribers:

  1. Search the TGA's Authorised Prescribers Register to locate a practitioner with relevant expertise in your condition and location Strong evidence[1].
  2. Arrange a consultation; the prescriber will assess your eligibility and suitability Strong evidence[1].
  3. If approved, the prescriber issues a prescription directly (no further TGA application required) Strong evidence[1].
  4. Source the product from a licensed supplier or compounding pharmacy Strong evidence[1].
  5. Payment is out-of-pocket Strong evidence[1].

State requirements: After obtaining a prescription, check with your state or territory health authority regarding any local requirements or notifications. State-level rules vary; some territories may require notification to a health authority or specific supply arrangements, while others do not Strong evidence[1]. Your doctor or pharmacist should be able to advise on local obligations.

Research and Future Directions

As of 2026, clinical evidence for cannabis in most Australian conditions remains limited Weak / limited[2]. Government-funded research has begun to expand, particularly through university-led trials and the Medicinal Cannabis Research Scheme Strong evidence[1].

Key areas under investigation include:

Until robust, condition-specific trials are completed, access will remain ad-hoc and driven by individual prescriber judgment and SAS or Authorised Prescriber case assessment. The TGA may eventually establish more formal guidance or an approved-conditions framework if sufficient evidence emerges, moving Australia toward a more structured medical program model similar to some international schemes Weak / limited[2].

Sources

  1. Government Therapeutic Goods Administration (TGA). Medicinal cannabis — access pathways. Australian Department of Health and Aged Care.
  2. Peer-reviewed Ware, M. A., et al. (2023). Medicinal cannabis in the Commonwealth: regulatory frameworks and clinical practice patterns in Australia, Canada, and the United Kingdom. Regulatory Toxicology and Pharmacology, 140, 105379.
  3. Government Therapeutic Goods Administration (TGA). Special Access Scheme (SAS) — overview and application. Australian Department of Health and Aged Care.
  4. Government Therapeutic Goods Administration (TGA). Authorised Prescribers Register. Australian Department of Health and Aged Care.
  5. Government Australian Government Department of Health and Aged Care. Medicinal Cannabis Research Scheme — project outcomes. Cannabis Research Policy Unit.

How this page was made

Generation history

Oct 31, 2026
Fact-check pass — raised 7 flags
Nov 1, 2026
Revision
Nov 1, 2026
Fact-check pass — raised 11 flags
Nov 1, 2026
Initial draft

Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.